Business Context and Reporting Period
This Form 8-K was filed by BioXcel Therapeutics, Inc. on April 1, 2026. The report details a regulatory milestone regarding the Company's product candidate, IGALMI, intended for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance metrics.
Material Changes
On April 1, 2026, the U.S. Food and Drug Administration (FDA) accepted the Company's supplemental New Drug Application (sNDA) for IGALMI. This acceptance marks a significant progression in the regulatory review process for the outpatient indication.
Guidance, Outlook, and Risks
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026. The filing does not provide specific management commentary on financial guidance, operational risks, or contingencies beyond the regulatory timeline.
Investor Verification Checklist
- Confirm the PDUFA target action date of November 14, 2026, for the IGALMI sNDA.
- Verify the specific scope of the supplemental application regarding the at-home (outpatient) setting.
- Monitor future filings for the FDA's final decision on the application.